MSD and Sun Pharmaceutical Industries have entered into a joint venture to bring branded generics to emerging markets.
The partnership will see the two develop, manufacture and commercialise new combinations and formulations of innovative generics.
Kevin Ali, President, Emerging Markets, MSD, says the partnership will provide a “solid foundation” for addressing the needs of “patients, physicians and governments” in emerging markets.
Experts predict that the burden of chronic diseases in emerging markets will drive 90% of the world’s pharmaceutical growth in the next ten years; with 75% of growth expected to come from branded generics.
The venture will be structured through the companies’ subsidiaries and will harness Sun’s product development experience and combine it with MSD’s clinical development and registration expertise.
The partnership will be managed by a joint board and a leadership team made up from senior management at both companies.
“This joint venture reinforces our strategy of partnering to launch products using our highly innovative delivery technologies around the world,” said Dilip Shanghvi, Chairman and Managing Director, Sun Pharmaceutical.